Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodevelopmental and Epilepsy Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GABRG2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GABRG2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GABRG2 Products |
| Gene Delivery | GABRG2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Crucial for functional channel assembly. |
View GABRG2 Products |
| Benchmark Ab | Anti-GABRG2 Recombinant Antibody Recombinant positive control for surface expression validation. |
View GABRG2 Products |
| Validator | GABRG2 siRNA Set For knockdown verification in target-specificity assays. |
View GABRG2 Products |
| Related Target A | GABRA1 Crucial alpha subunit partnering with GABRG2 to form functional heteropentameric GABA-A channels. |
View GABRA1 Products |
| Related Target B | GABRB2 Beta subunit essential for reconstituting native GABA-A receptor pharmacology in vitro. |
View GABRB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-subunit Assembly Verification | Lentiviruses for GABRG2, GABRA1, and GABRB2 available for co-transduction and stable stoichiometry. |
| Subtype-Selective Screening | Homolog panel proteins (Gamma-1, Gamma-3) strictly verified by mass spectrometry to eliminate cross-reactivity. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control ligands. |
| False Positives in Binding | Sequence-verified siRNA included for target knockdown and specificity validation. |
Live GABRG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GABRG2 therapeutics is intensifying, with major players shifting focus from traditional non-selective benzodiazepines to subtype-selective Positive Allosteric Modulators (PAMs) and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting specific genetic mutations (such as those causing Dravet syndrome and childhood absence epilepsy) to achieve precision neuro-therapeutics without the sedative side effects of classical GABAergic drugs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAM) | Sage Therapeutics, Neurocrine Biosciences | Epilepsy, Genetic Seizure Disorders | Multi-subunit stable cell line construction (Need functional Lentivirus) |
| Gene Therapy (AAV/Lenti) | Encoded Therapeutics, Stoke Therapeutics | Dravet Syndrome, CAE | Expression validation and knockdown controls (Need siRNA and validated Antibodies) |
| Subtype-Selective Antibody | Academic/Biotech Consortia | Neuroinflammation, Insomnia | Conformation-specific binding assays (Need high-purity ECD-Fc proteins) |